Search results for "Immunosuppressive"

showing 10 items of 293 documents

Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alco…

2008

Hepatitis C virus (HCV)-related liver disease is enhanced by alcohol consumption. Of HCV-related liver transplantation (LT) recipients, 25% have a history of alcohol intake. The purpose of this research was to determine whether LT outcome differs between patients with cirrhosis of mixed etiology compared to HCV or alcohol alone. Of 494 LT (1997-2001), recipient/donor features, post-LT histological, metabolic complications [hypertension, diabetes-diabetes mellitus (DM)], and de novo tumors were compared in 3 groups [HCV-related cirrhosis = 170 (HCV group), alcohol-related cirrhosis (alcohol group) = 107, and cirrhosis of mixed etiology (mixed group) = 60]. Protocol biopsies were done in HCV …

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentHepacivirusLiver transplantationmedicine.disease_causeGastroenterologyBody Mass IndexLiver diseasePostoperative ComplicationsLiver Cirrhosis AlcoholicInternal medicineHumansMedicineAgedTransplantationHepatologybusiness.industryIncidence (epidemiology)Graft Survivalvirus diseasesMiddle Agedmedicine.diseaseHepatitis Cdigestive system diseasesLiver TransplantationTreatment OutcomeHepatocellular carcinomaEtiologyFemaleSurgerybusinessBody mass indexImmunosuppressive AgentsLiver Transplantation
researchProduct

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

2021

Abstract Introduction With the increasing use of checkpoint inhibitors, rare immune-related adverse events (irAE) are being identified. Haematological irAE (hem-irAE) are difficult to treat and have shown high mortality rates. In order to improve side-effect management for these potentially life-threatening events, we analysed frequency, severity and outcomes. Patients and methods Patients who developed hem-irAE while being treated with immune checkpoint inhibitors (ICI) therapy were retrospectively identified from 18 international cancer centres. Results In total, more than 7626 patients treated with ICI were screened, and 50 patients with hem-irAE identified. The calculated incidence amou…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyNeutropeniamedicine.medical_treatmentMedizinNeutropeniamedicine.disease_causeGastroenterologyAutoimmunityYoung Adult03 medical and health sciences0302 clinical medicineImmune systemAdrenal Cortex HormonesInternal medicinemedicineHumansAdverse effectImmune Checkpoint InhibitorsAgedRetrospective StudiesAged 80 and overHemophagocytic lymphohistiocytosisbusiness.industryIncidenceIncidence (epidemiology)CancerAnemiaImmunosuppressionMiddle Agedmedicine.diseaseThrombocytopeniaTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemalebusinessImmunosuppressive Agents
researchProduct

Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study

2017

Abstract Background aims Despite the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), the procedure is still associated with high toxicity in patients with refractory graft-versus-host disease (GvHD). Mesenchymal stromal cells (MSCs) are a new mode of therapy in the context of allo-HSCT. The objective of this study was to evaluate the safety and feasibility of the use of adipose tissue–derived MSCs (AT-MSCs) in patients with chronic GvHD. Methods Fourteen patients with moderate (n = 7) or severe (n = 7) chronic GvHD received 1 × 106/kg (group A, n = 9) or 3 × 106/kg (group B, n = 5) AT-MSCs with cyclosporine and prednisone as first-line therapy. Results Ten of the…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentImmunologyGraft vs Host DiseaseAdipose tissueContext (language use)DiseaseHematopoietic stem cell transplantationMesenchymal Stem Cell TransplantationGastroenterology03 medical and health sciencesPrednisoneInternal medicinemedicineHumansImmunology and AllergyGenetics (clinical)TransplantationTumor Necrosis Factor-alphabusiness.industryMesenchymal stem cellMesenchymal Stem CellsCell BiologyMiddle Agedmedicine.diseaseKiller Cells NaturalTreatment Outcome030104 developmental biologyGraft-versus-host diseaseAdipose TissueOncologyToxicityImmunologyCyclosporinePrednisoneFemalebusinessImmunosuppressive Agentsmedicine.drugCytotherapy
researchProduct

Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis

2017

Abstract The therapeutic mode of action of dimethyl fumarate (DMF), approved for treating patients with relapsing-remitting multiple sclerosis, is not fully understood. Recently, we and others demonstrated that Ab-independent functions of distinct B cell subsets are important in mediating multiple sclerosis (MS) relapsing disease activity. Our objective was to test whether and how DMF influences both the phenotype and functional responses of disease-implicated B cell subsets in patients with MS. High-quality PBMC were obtained from relapsing-remitting MS patients prior to and serially after initiation of DMF treatment. Multiparametric flow cytometry was used to monitor the phenotype and fun…

AdultMale0301 basic medicineDimethyl FumarateImmunologyNaive B cellB-Lymphocyte SubsetsEnzyme-Linked Immunosorbent AssayBiologyPeripheral blood mononuclear cellProinflammatory cytokineFlow cytometryYoung Adult03 medical and health scienceschemistry.chemical_compoundMultiple Sclerosis Relapsing-Remitting0302 clinical medicineIn vivomedicineHumansImmunology and AllergyB cellmedicine.diagnostic_testDimethyl fumarateMultiple sclerosisMiddle AgedFlow Cytometrymedicine.disease030104 developmental biologymedicine.anatomical_structurechemistryImmunologyCancer researchFemaleImmunosuppressive Agents030217 neurology & neurosurgeryThe Journal of Immunology
researchProduct

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS

2017

Background: The effect of dimethyl fumarate (DMF) on circulating lymphocyte subsets and their contribution as predictors of clinical efficacy have not yet been investigated in multiple sclerosis (MS). Objective: To evaluate lymphocytes and lymphocyte subsets (analyzed 6 months after DMF start) in MS patients with and without disease activity after 1 year of treatment in a retrospective study. Methods: Peripheral blood lymphocyte subsets were analyzed by flow cytometry. Untreated MS patients ( n = 40) were compared to those 6 months after onset of DMF treatment ( n = 51). Clinical and magnetic resonance imaging (MRI) disease activity of DMF-treated patients were assessed in the first year un…

AdultMale0301 basic medicineTreatment responseMultiple SclerosisAdolescentDimethyl FumarateAntigens CD19CD4-CD8 RatioCD8-Positive T-LymphocytesPharmacologyStatistics NonparametricReduction (complexity)Young Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineText miningLymphopeniamedicineHumansCytotoxic T cellLongitudinal StudiesLymphocyte CountClinical efficacyRetrospective StudiesB-LymphocytesDimethyl fumarateChemistrybusiness.industryMultiple sclerosisMiddle AgedFlow Cytometrymedicine.diseaseMagnetic Resonance ImagingCross-Sectional StudiesTreatment Outcome030104 developmental biologyROC CurveNeurologyDisease ProgressionFemaleNeurology (clinical)businessImmunosuppressive Agents030217 neurology & neurosurgeryFollow-Up StudiesLymphocyte subsetsMultiple Sclerosis Journal
researchProduct

Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine

2017

Purpose To investigate the effect of cyclosporine on corneal ultrastructure and on major signs and symptoms of patients with dry eye disease.Patients and methods In this prospective cohort study, patients with dry eye disease were treated with a drop of cyclosporine 0.05% twice daily. Clinical evaluation was carried out at baseline and at months 1, 3, and 6. All patients completed the Ocular Surface Disease Index (OSDI) questionnaire, and tear film break-up time (BUT), fluorescein and lissamine green staining, and Schirmer test were carried out. In vivo confocal microscopy was also performed and epithelial cellular density, keratocyte activation, and subbasal plexus morphology were assessed…

AdultMale0301 basic medicinemedicine.medical_specialtyAdministration TopicalConfocalDry Eye SyndromesGlaucomaCell CountOphthalmic SolutionFollow-Up StudieCorneaImmunosuppressive Agent03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOphthalmologyCorneamedicineOcular Surface Disease IndexFluoresceinProspective cohort studyAgedMicroscopy Confocalbusiness.industryMiddle Agedmedicine.diseaseStainingProspective StudieOphthalmologyTreatment Outcome030104 developmental biologymedicine.anatomical_structureNerve FiberchemistryCyclosporine030221 ophthalmology & optometryFemalebusinessDry Eye SyndromeHumanEye
researchProduct

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

2021

AdultMale2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)prospective cohortMEDLINEDermatologyregistryimmunosuppressive agentsSeverity of Illness IndexCOVID-19 (Malaltia)ArticleCohort StudiesInternal medicinePandemicPsoriasisHumansMedicinebiologic therapyRegistriesAgedbusiness.industryIncidenceIncidence (epidemiology)COVID-19COVID-19 Psoriasis biologic therapy immunosuppressive agents pharmacovigilance prospective cohort registryMiddle AgedSpainpharmacovigilanceFemalebusinessPsoriasi -- TractamentCohort studyJournal of the American Academy of Dermatology
researchProduct

Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus.

2010

BACKGROUND: One of the major goals of pemphigus therapy is to reduce the patient's cumulative exposure to systemic corticosteroids. To investigate the efficacy of enteric-coated mycophenolate sodium (EC-MPS), 10 patients with active, refractory pemphigus vulgaris (PV) or foliaceous (PF) were treated with EC-MPS (1440 mg daily) and prednisone (75 mg daily) over 18 months. OBSERVATIONS: Following EC-MPS/prednisone therapy, disease progression was inhibited between days 30 and 45 in 9/10 patients (8 PV; 1 PF). At 18 months, 8/9 PV patients had clinically quiescent disease; EC-MPS therapy was no longer required in two patients as a result of disease remission. The remaining PV patient showed no…

AdultMaleAdministration OralMiddle AgedMycophenolic AcidTreatment OutcomeSettore MED/35 - Malattie Cutanee E VenereeEnteric-coated Mycophenolate SodiumHumansPrednisoneDrug Therapy CombinationFemaleTablets Enteric-CoatedGlucocorticoidsImmunosuppressive AgentsPemphigusFollow-Up StudiesInternational journal of dermatology
researchProduct

Fatigue in SLE: diagnostic and pathogenic impact of anti-N-methyl-D-aspartate receptor (NMDAR) autoantibodies.

2019

ObjectivesWe explored the impact of circulating anti-N-methyl-D-aspartate receptor (NMDAR) antibodies on the severity of fatigue in patients with systemic lupus erythematosus (SLE).MethodsSerum samples of 426 patients with SLE were analysed for the presence of antibodies to the NR2 subunit of the NMDAR. In parallel, the severity of fatigue was determined according to the Fatigue Scale for Motor and Cognitive functions questionnaire. In a subgroup of patients with SLE, the hippocampal volume was correlated with the levels of anti-NR2 antibodies. Isolated immunoglobulin G from patients with anti-NR2 antibodies were used for murine immunohistochemical experiments and functional assays on neuro…

AdultMaleAdolescentImmunologyEnzyme-Linked Immunosorbent AssayAntibodies Monoclonal HumanizedReceptors N-Methyl-D-AspartateSeverity of Illness IndexGeneral Biochemistry Genetics and Molecular BiologyImmunoglobulin GCell Line03 medical and health sciencesYoung Adult0302 clinical medicineCerebrospinal fluidRheumatologymedicineImmunology and AllergyHumansLupus Erythematosus SystemicReceptorFatigueAgedAutoantibodies030203 arthritis & rheumatologySystemic lupus erythematosusbiologybusiness.industryAutoantibodyMiddle Agedmedicine.diseaseBelimumabImmunologybiology.proteinImmunohistochemistryFemaleAntibodybusiness030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugAnnals of the rheumatic diseases
researchProduct

Cyclosporin- and nifedipine-induced gingival overgrowth in renal transplant patients: correlations with periodontal and pharmacological parameters, a…

1996

The factors associated with cyclosporin A (CsA)- and nifedipine (Nif)-induced gingival overgrowth were investigated in 113 renal transplant recipients receiving CsA alone (Group 1) [n = 61], CsA and Nif (Group 2) [n = 28], or azathioprine (Aza) (Control Group) [n = 24]. Periodontal and pharmacological parameters were assessed for each patient. The patients with a gingival overgrowth index (GOI) score1 were considered responders (R); those with a score/= 1 were non-responders (NR). Gingival overgrowth occurred in 33.7% of the patients in Groups 1 and 2; 60% of the responders were receiving CsA+Nif. In R, no relationship was found between the GOI and the periodontal and pharmacological parame…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentNifedipineAzathioprineGastroenterologyPathology and Forensic MedicinePathogenesisNifedipineHLA AntigensInternal medicineCyclosporin aAzathioprinePrevalencemedicineHumansPeriodontal PocketDental CalculusChildSalivaKidney transplantationKidneyHLA-A AntigensGingival Overgrowthbusiness.industryDental Plaque IndexMiddle AgedCalcium Channel Blockersmedicine.diseaseGingivitisKidney TransplantationTransplantationEndocrinologymedicine.anatomical_structureOtorhinolaryngologyToxicityCyclosporineIrritantsPeriodonticsFemaleDisease SusceptibilityPeriodontal IndexOral SurgerybusinessImmunosuppressive Agentsmedicine.drugJournal of Oral Pathology and Medicine
researchProduct